Galapagos Lands US$1.35 B Deal with Abbott for Phase II JAK Inhibitor
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 3 (Table of Contents)
Published: 6 Mar-2012
DOI: 10.3833/pdr.v2012.i3.1693 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Abbott has gained rights to Galapagos’ rheumatoid arthritis (RA) drug candidate GLPG0634 as part of a collaboration worth as much as US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS